6533b862fe1ef96bd12c64a4

RESEARCH PRODUCT

Treat-to-target versus dose-adapted statin treatment of cholesterol to reduce cardiovascular risk

Eduardo FarinaroWalter F. RiesenRafael CarmenaDirk Müller-wielandEvgenyi ShlyakhtoGerd AssmannArnold Von EckardsteinAnders G. OlssonJean DavignonHeiner Greten

subject

medicine.medical_specialtyConsensusStatinEpidemiologymedicine.drug_classHypercholesterolemia610 Medicine & healthComorbidity030204 cardiovascular system & hematologyRisk Assessment2705 Cardiology and Cardiovascular MedicinePatient care03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRisk Factors540 ChemistrymedicineHumans030212 general & internal medicineIntensive care medicine10038 Institute of Clinical Chemistrybusiness.industryCholesterolTreat to targetCholesterol LDLGuidelineStatin treatmentTreatment OutcomechemistryCardiovascular DiseasesPractice Guidelines as TopicPhysical therapyLDL Cholesterol Lipoproteinslipids (amino acids peptides and proteins)Disease preventionHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessBiomarkers2713 Epidemiology

description

Clinical guidelines should be based on the best available evidence and are of great importance for patient care and disease prevention. In this respect, the 2013 American College of Cardiology/American Heart Association report is highly appreciated and well-recognized. The report included critical questions concerning hypercholesterolaemia, but its translation into a clinical guideline initiated intense debate worldwide because of the recommendation to switch from a treat-to-target approach for low-density-lipoprotein-cholesterol to a statin dose-based strategy.

yearjournalcountryeditionlanguage
2015-01-16European Journal of Preventive Cardiology
https://doi.org/10.1177/2047487314567001